JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

ACADIA Pharmaceuticals Inc

Închisă

SectorSănătate

22.02 1.62

Rezumat

Modificarea prețului

24h

Curent

Minim

21.92

Maxim

22.18

Indicatori cheie

By Trading Economics

Venit

7.7M

27M

Vânzări

20M

265M

P/E

Medie Sector

15.744

37.461

Marjă de profit

10.079

Angajați

653

EBITDA

21M

40M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+34.47% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-491M

3.5B

Deschiderea anterioară

20.4

Închiderea anterioară

22.02

Sentimentul știrilor

By Acuity

67%

33%

319 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

ACADIA Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 oct. 2025, 18:41 UTC

Câștiguri

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 oct. 2025, 18:31 UTC

Câștiguri

Correction to Procter & Gamble to Focus on Innovation

24 oct. 2025, 16:25 UTC

Principalele dinamici ale pieței

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 oct. 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 oct. 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 oct. 2025, 21:07 UTC

Câștiguri

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 oct. 2025, 20:58 UTC

Câștiguri

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 oct. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24 oct. 2025, 20:40 UTC

Câștiguri

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 oct. 2025, 20:24 UTC

Câștiguri

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct. 2025, 20:23 UTC

Câștiguri

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct. 2025, 20:13 UTC

Câștiguri

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct. 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 oct. 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 oct. 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 oct. 2025, 19:33 UTC

Câștiguri

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 oct. 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 oct. 2025, 18:52 UTC

Câștiguri

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct. 2025, 18:41 UTC

Câștiguri

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct. 2025, 18:03 UTC

Câștiguri

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 oct. 2025, 18:02 UTC

Câștiguri

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 oct. 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 oct. 2025, 16:57 UTC

Câștiguri

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 oct. 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 oct. 2025, 16:44 UTC

Market Talk
Câștiguri

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 oct. 2025, 16:39 UTC

Market Talk
Câștiguri

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 oct. 2025, 16:33 UTC

Câștiguri

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct. 2025, 16:23 UTC

Câștiguri

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24 oct. 2025, 16:07 UTC

Câștiguri

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Comparație

Modificare preț

ACADIA Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

34.47% sus

Prognoză pe 12 luni

Medie 29.61 USD  34.47%

Maxim 39 USD

Minim 17 USD

În baza a 19 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruACADIA Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

19 ratings

13

Cumpărare

5

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

14.845 / N/ASuport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Neutral Evidence

Sentiment

By Acuity

319 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
help-icon Live chat